Trial Profile
A Double-blind, Placebo-controlled, Phase 2 Dose-range Study to Assess the Efficacy and Safety of WP1302 in Preventing Disease Relapse Following Methimazole Withdrawal in Subjects With Graves' Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs ATX-GD 59 (Primary) ; Thiamazole
- Indications Graves' disease
- Focus Therapeutic Use
- Sponsors Worg Pharmaceuticals (Hangzhou)
- 02 Feb 2024 Status changed from planning to recruiting.
- 19 Mar 2018 According to an Apitope website (https://apitope.com/graves-disease/), this trial is expected to initiate in the first quarter of 2019.
- 19 Mar 2018 New trial record